The apparent synergy between GLP-1R mimetics and GIPR antagonists has been exploited elsewhere in the pursuit of GIP MABs for obesity management (Fig. 1). The gene discussed is GLP1R; the disease is obesity due to melanocortin 4 receptor deficiency.